These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31262654)

  • 1. Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Heinrich S
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):305-306. PubMed ID: 31262654
    [No Abstract]   [Full Text] [Related]  

  • 2. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
    Hackert T; Ulrich A; Büchler MW
    Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
    [No Abstract]   [Full Text] [Related]  

  • 3. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular Resections During the Whipple Procedure.
    Maley WR; Yeo CJ
    Adv Surg; 2017 Sep; 51(1):41-63. PubMed ID: 28797345
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
    Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
    Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
    Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
    Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy for resectable pancreatic cancer.
    Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
    Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment.
    Borgida AE; Ashamalla S; Al-Sukhni W; Rothenmund H; Urbach D; Moore M; Cotterchio M; Gallinger S
    Can J Surg; 2011 Feb; 54(1):54-60. PubMed ID: 21251433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas.
    Meszoely IM; Lee JS; Watson JC; Meyers M; Wang H; Hoffman JP
    Am Surg; 2004 Mar; 70(3):208-13; discussion 213-4. PubMed ID: 15055843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy.
    Hwang HK; Jung MJ; Lee SH; Kang CM; Lee WJ
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):497-507. PubMed ID: 27295957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total pancreatectomy: indications, different timing, and perioperative and long-term outcomes.
    Crippa S; Tamburrino D; Partelli S; Salvia R; Germenia S; Bassi C; Pederzoli P; Falconi M
    Surgery; 2011 Jan; 149(1):79-86. PubMed ID: 20494386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors following curative resection for pancreatic adenocarcinoma.
    Jeekel H
    Ann Surg; 2004 Aug; 240(2):384. PubMed ID: 15273566
    [No Abstract]   [Full Text] [Related]  

  • 17. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique?
    Cho CS; Kooby DA; Schmidt CM; Nakeeb A; Bentrem DJ; Merchant NB; Parikh AA; Martin RC; Scoggins CR; Ahmad SA; Kim HJ; Hamilton N; Hawkins WG; Weber SM
    Ann Surg; 2011 May; 253(5):975-80. PubMed ID: 21394014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
    Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
    Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.